Thank You for Joining Us and Your Colleagues World Experts Your Friends

Thank you for your participation in SH-EA4HP 2023!

Recordings of each workshop session are now available to workshop registrants for no additional charge! You may view these recordings in on-demand format until December 20th. After this date, access to the recordings will be removed and you will no longer be able to access them.

Did You Miss SH-EA4HP 2023?

Anyone may purchase access to the SH-EA4HP session recordings. Purchased recording access will expire on December 20th regardless of the purchase date, so please do not wait to purchase your access. To purchase access, please visit the workshop registration system and select the "ON-DEMAND RECORDINGS" registration option. Please note that "ON-DEMAND RECORDINGS" registrations do not include CME.

Stay tuned for the announcement of SH-EA4HP 2025, coming soon!

Peripheral T- and NK-cell lymphomas are a heterogeneous and often clinically aggressive group of neoplasms. These neoplasms are rare and usually diagnostically challenging. Our understanding of the pathogenesis of these neoplasms is increasing and this improved knowledge is leading us to better molecular characterization, more objective and accurate diagnostic criteria, more effective risk assessment, and potentially better treatments.

The focus of this workshop is to provide a comprehensive review of the clinicopathological and molecular features of these neoplasms with an interest in addressing commonly encountered diagnostic problems and highlighting novel and emerging biomarkers that can assist in the diagnosis, classification, prognosis and/or treatment of these neoplasms.

Also, we will use high throughput genomics (WES, nanostring/GEP and RNAseq) to assist in the diagnosis and to identify molecularly defined subgroups inside the major subtypes of PTCLs. We will compare the conventional diagnostic approach with the nanostring results. Genomic analysis will be performed in a subset of cases including peripheral T-cell lymphomas (PTCL) with a T follicular helper (TFH) phenotype including angioimmunoblastic T cell lymphoma, PTCL-GATA3 and TBX21, nodal cytotoxic PTCL and Lennert lymphoma.

Francisco Vega, MD PhD

Workshop Chair

L. Jeffrey Medeiros, MD

Workshop Co-Chair

Carlos E. Bueso-Ramos, MD PhD

Workshop Co-Chair

Javeed Iqbal, PhD

Workshop Co-Chair

Workshop Committee

James Cook, MD, PhD
Robert Hasserjian, MD
Sa A. Wang, MD
Roberto N. Miranda, MD
Mark Routbort, MD, PhD
Sanam Loghavi, MD
Jie Xu, MD
Keyur Pravinchandra Patel, MD
Rashmi Shamanna Kanagal, MD